Reputation and power: organizational image and pharmaceutical regulation at the FDA
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Princeton
Princeton University Press
©2010
|
| Schriftenreihe: | Princeton studies in American politics
|
| Schlagworte: | |
| Online-Zugang: | FAW01 FAW02 Volltext |
| Beschreibung: | Includes bibliographical references and index Introduction - The gatekeeper -- - Reputation and regulatory power -- - Reputation and gatekeeping authority : the federal Food, Drug, and Cosmetic Act of 1938 and its aftermath -- - The ambiguous emergence of American pharmaceutical regulation, 1944-1961 -- - Reputation and power crystallized : thalidomide, Frances Kelsey, and phased experiment, 1961-1966 -- - Reputation and power institutionalized : scientific networks, congressional hearings, and judicial affirmations, 1963-1986 -- - Reputation and power contested : emboldened audiences in cancer and AIDS, 1977-1992 -- - Reputation and the organizational politics of new drug review -- - The governance of research and development : gatekeeping power, conceptual guidance, and regulation by satellite -- - The other side of the gate : reputation, power, and post-market regulation -- - The détenté of firm and regulator -- - American pharmaceutical regulations in international context : audiences, comparisons, and dependencies -- - Conclusion - A reputation in brief The U.S. Food and Drug Administration is the most powerful regulatory agency in the world. How did the FDA become so influential? And how exactly does it wield its extraordinary power? Reputation and Power traces the history of FDA regulation of pharmaceuticals, revealing how the agency's organizational reputation has been the primary source of its power, yet also one of its ultimate constraints. Daniel Carpenter describes how the FDA cultivated a reputation for competence and vigilance throughout the last century, and how this organizational image has enabled the agency to regulate an industr |
| Beschreibung: | 1 Online-Ressource (xx, 802 pages) |
| ISBN: | 0691141800 1400835119 9780691141800 9781400835119 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043077668 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 151126s2010 |||| o||u| ||||||eng d | ||
| 020 | |a 0691141800 |c pbk. : alk. paper |9 0-691-14180-0 | ||
| 020 | |a 1400835119 |c electronic bk. |9 1-4008-3511-9 | ||
| 020 | |a 9780691141800 |c pbk. : alk. paper |9 978-0-691-14180-0 | ||
| 020 | |a 9781400835119 |c electronic bk. |9 978-1-4008-3511-9 | ||
| 035 | |a (OCoLC)655342133 | ||
| 035 | |a (DE-599)BVBBV043077668 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1046 |a DE-1047 | ||
| 082 | 0 | |a 362.17/82 |2 22 | |
| 084 | |a LC 18610 |0 (DE-625)90627:983 |2 rvk | ||
| 084 | |a MS 6410 |0 (DE-625)123754: |2 rvk | ||
| 100 | 1 | |a Carpenter, Daniel P. |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Reputation and power |b organizational image and pharmaceutical regulation at the FDA |c Daniel Carpenter |
| 264 | 1 | |a Princeton |b Princeton University Press |c ©2010 | |
| 300 | |a 1 Online-Ressource (xx, 802 pages) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Princeton studies in American politics | |
| 500 | |a Includes bibliographical references and index | ||
| 500 | |a Introduction - The gatekeeper -- - Reputation and regulatory power -- - Reputation and gatekeeping authority : the federal Food, Drug, and Cosmetic Act of 1938 and its aftermath -- - The ambiguous emergence of American pharmaceutical regulation, 1944-1961 -- - Reputation and power crystallized : thalidomide, Frances Kelsey, and phased experiment, 1961-1966 -- - Reputation and power institutionalized : scientific networks, congressional hearings, and judicial affirmations, 1963-1986 -- - Reputation and power contested : emboldened audiences in cancer and AIDS, 1977-1992 -- - Reputation and the organizational politics of new drug review -- - The governance of research and development : gatekeeping power, conceptual guidance, and regulation by satellite -- - The other side of the gate : reputation, power, and post-market regulation -- - The détenté of firm and regulator -- - American pharmaceutical regulations in international context : audiences, comparisons, and dependencies -- - Conclusion - A reputation in brief | ||
| 500 | |a The U.S. Food and Drug Administration is the most powerful regulatory agency in the world. How did the FDA become so influential? And how exactly does it wield its extraordinary power? Reputation and Power traces the history of FDA regulation of pharmaceuticals, revealing how the agency's organizational reputation has been the primary source of its power, yet also one of its ultimate constraints. Daniel Carpenter describes how the FDA cultivated a reputation for competence and vigilance throughout the last century, and how this organizational image has enabled the agency to regulate an industr | ||
| 610 | 1 | 4 | |a United States / Food and Drug Administration |
| 610 | 1 | 7 | |a United States / Food and Drug Administration |2 fast |
| 610 | 2 | 4 | |a United States |b Food and Drug Administration |
| 610 | 2 | 7 | |a USA |b Food and Drug Administration |0 (DE-588)10985-X |2 gnd |9 rswk-swf |
| 648 | 7 | |a Geschichte 1927-2010 |2 gnd |9 rswk-swf | |
| 650 | 4 | |a Drug Approval / United States | |
| 650 | 4 | |a Consumer Product Safety / United States | |
| 650 | 4 | |a Government Agencies / United States / History | |
| 650 | 4 | |a Government Regulation / United States | |
| 650 | 4 | |a Organizational Culture / United States | |
| 650 | 4 | |a Drugs | |
| 650 | 4 | |a Food and Drug Administration | |
| 650 | 4 | |a Pharmaceutical policy | |
| 650 | 4 | |a Research | |
| 650 | 4 | |a United States | |
| 650 | 4 | |a Health | |
| 650 | 4 | |a Political Science | |
| 650 | 4 | |a Social Science | |
| 650 | 7 | |a MEDICAL / Allied Health Services / General |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Pharmacology |2 bisacsh | |
| 650 | 7 | |a Drugs / Research |2 fast | |
| 650 | 7 | |a Pharmaceutical policy |2 fast | |
| 650 | 4 | |a Geschichte | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Pharmaceutical policy |z United States | |
| 650 | 4 | |a Drugs |x Research |z United States | |
| 650 | 0 | 7 | |a Machtzuwachs |0 (DE-588)7545408-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Organisationsstruktur |0 (DE-588)4115464-2 |2 gnd |9 rswk-swf |
| 651 | 4 | |a USA | |
| 689 | 0 | 0 | |a USA |b Food and Drug Administration |0 (DE-588)10985-X |D b |
| 689 | 0 | 1 | |a Organisationsstruktur |0 (DE-588)4115464-2 |D s |
| 689 | 0 | 2 | |a Machtzuwachs |0 (DE-588)7545408-7 |D s |
| 689 | 0 | 3 | |a Geschichte 1927-2010 |A z |
| 689 | 0 | |8 1\p |5 DE-604 | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druckausgabe |z 0-691-14179-7 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druckausgabe |z 978-0-691-14179-4 |
| 856 | 4 | 0 | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=329845 |x Aggregator |3 Volltext |
| 912 | |a ZDB-4-EBA | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-028501860 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=329845 |l FAW01 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=329845 |l FAW02 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804175466749231104 |
|---|---|
| any_adam_object | |
| author | Carpenter, Daniel P. |
| author_facet | Carpenter, Daniel P. |
| author_role | aut |
| author_sort | Carpenter, Daniel P. |
| author_variant | d p c dp dpc |
| building | Verbundindex |
| bvnumber | BV043077668 |
| classification_rvk | LC 18610 MS 6410 |
| collection | ZDB-4-EBA |
| ctrlnum | (OCoLC)655342133 (DE-599)BVBBV043077668 |
| dewey-full | 362.17/82 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 362 - Social problems and services to groups |
| dewey-raw | 362.17/82 |
| dewey-search | 362.17/82 |
| dewey-sort | 3362.17 282 |
| dewey-tens | 360 - Social problems and services; associations |
| discipline | Soziologie Sozial-/Kulturanthropologie / Empirische Kulturwissenschaft |
| era | Geschichte 1927-2010 gnd |
| era_facet | Geschichte 1927-2010 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05210nmm a2200865zc 4500</leader><controlfield tag="001">BV043077668</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">151126s2010 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0691141800</subfield><subfield code="c">pbk. : alk. paper</subfield><subfield code="9">0-691-14180-0</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1400835119</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">1-4008-3511-9</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780691141800</subfield><subfield code="c">pbk. : alk. paper</subfield><subfield code="9">978-0-691-14180-0</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781400835119</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">978-1-4008-3511-9</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)655342133</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043077668</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1046</subfield><subfield code="a">DE-1047</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">362.17/82</subfield><subfield code="2">22</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">LC 18610</subfield><subfield code="0">(DE-625)90627:983</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">MS 6410</subfield><subfield code="0">(DE-625)123754:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Carpenter, Daniel P.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Reputation and power</subfield><subfield code="b">organizational image and pharmaceutical regulation at the FDA</subfield><subfield code="c">Daniel Carpenter</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Princeton</subfield><subfield code="b">Princeton University Press</subfield><subfield code="c">©2010</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (xx, 802 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Princeton studies in American politics</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Introduction - The gatekeeper -- - Reputation and regulatory power -- - Reputation and gatekeeping authority : the federal Food, Drug, and Cosmetic Act of 1938 and its aftermath -- - The ambiguous emergence of American pharmaceutical regulation, 1944-1961 -- - Reputation and power crystallized : thalidomide, Frances Kelsey, and phased experiment, 1961-1966 -- - Reputation and power institutionalized : scientific networks, congressional hearings, and judicial affirmations, 1963-1986 -- - Reputation and power contested : emboldened audiences in cancer and AIDS, 1977-1992 -- - Reputation and the organizational politics of new drug review -- - The governance of research and development : gatekeeping power, conceptual guidance, and regulation by satellite -- - The other side of the gate : reputation, power, and post-market regulation -- - The détenté of firm and regulator -- - American pharmaceutical regulations in international context : audiences, comparisons, and dependencies -- - Conclusion - A reputation in brief</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">The U.S. Food and Drug Administration is the most powerful regulatory agency in the world. How did the FDA become so influential? And how exactly does it wield its extraordinary power? Reputation and Power traces the history of FDA regulation of pharmaceuticals, revealing how the agency's organizational reputation has been the primary source of its power, yet also one of its ultimate constraints. Daniel Carpenter describes how the FDA cultivated a reputation for competence and vigilance throughout the last century, and how this organizational image has enabled the agency to regulate an industr</subfield></datafield><datafield tag="610" ind1="1" ind2="4"><subfield code="a">United States / Food and Drug Administration</subfield></datafield><datafield tag="610" ind1="1" ind2="7"><subfield code="a">United States / Food and Drug Administration</subfield><subfield code="2">fast</subfield></datafield><datafield tag="610" ind1="2" ind2="4"><subfield code="a">United States</subfield><subfield code="b">Food and Drug Administration</subfield></datafield><datafield tag="610" ind1="2" ind2="7"><subfield code="a">USA</subfield><subfield code="b">Food and Drug Administration</subfield><subfield code="0">(DE-588)10985-X</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="648" ind1=" " ind2="7"><subfield code="a">Geschichte 1927-2010</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Approval / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Consumer Product Safety / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Government Agencies / United States / History</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Government Regulation / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Organizational Culture / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Food and Drug Administration</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical policy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Research</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Health</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Political Science</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Social Science</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Allied Health Services / General</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drugs / Research</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical policy</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Geschichte</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical policy</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="x">Research</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Machtzuwachs</subfield><subfield code="0">(DE-588)7545408-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Organisationsstruktur</subfield><subfield code="0">(DE-588)4115464-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">USA</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">USA</subfield><subfield code="b">Food and Drug Administration</subfield><subfield code="0">(DE-588)10985-X</subfield><subfield code="D">b</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Organisationsstruktur</subfield><subfield code="0">(DE-588)4115464-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Machtzuwachs</subfield><subfield code="0">(DE-588)7545408-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Geschichte 1927-2010</subfield><subfield code="A">z</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druckausgabe</subfield><subfield code="z">0-691-14179-7</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druckausgabe</subfield><subfield code="z">978-0-691-14179-4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=329845</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028501860</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=329845</subfield><subfield code="l">FAW01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=329845</subfield><subfield code="l">FAW02</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| geographic | USA |
| geographic_facet | USA |
| id | DE-604.BV043077668 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:16:44Z |
| institution | BVB |
| isbn | 0691141800 1400835119 9780691141800 9781400835119 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028501860 |
| oclc_num | 655342133 |
| open_access_boolean | |
| owner | DE-1046 DE-1047 |
| owner_facet | DE-1046 DE-1047 |
| physical | 1 Online-Ressource (xx, 802 pages) |
| psigel | ZDB-4-EBA ZDB-4-EBA FAW_PDA_EBA |
| publishDate | 2010 |
| publishDateSearch | 2010 |
| publishDateSort | 2010 |
| publisher | Princeton University Press |
| record_format | marc |
| series2 | Princeton studies in American politics |
| spelling | Carpenter, Daniel P. Verfasser aut Reputation and power organizational image and pharmaceutical regulation at the FDA Daniel Carpenter Princeton Princeton University Press ©2010 1 Online-Ressource (xx, 802 pages) txt rdacontent c rdamedia cr rdacarrier Princeton studies in American politics Includes bibliographical references and index Introduction - The gatekeeper -- - Reputation and regulatory power -- - Reputation and gatekeeping authority : the federal Food, Drug, and Cosmetic Act of 1938 and its aftermath -- - The ambiguous emergence of American pharmaceutical regulation, 1944-1961 -- - Reputation and power crystallized : thalidomide, Frances Kelsey, and phased experiment, 1961-1966 -- - Reputation and power institutionalized : scientific networks, congressional hearings, and judicial affirmations, 1963-1986 -- - Reputation and power contested : emboldened audiences in cancer and AIDS, 1977-1992 -- - Reputation and the organizational politics of new drug review -- - The governance of research and development : gatekeeping power, conceptual guidance, and regulation by satellite -- - The other side of the gate : reputation, power, and post-market regulation -- - The détenté of firm and regulator -- - American pharmaceutical regulations in international context : audiences, comparisons, and dependencies -- - Conclusion - A reputation in brief The U.S. Food and Drug Administration is the most powerful regulatory agency in the world. How did the FDA become so influential? And how exactly does it wield its extraordinary power? Reputation and Power traces the history of FDA regulation of pharmaceuticals, revealing how the agency's organizational reputation has been the primary source of its power, yet also one of its ultimate constraints. Daniel Carpenter describes how the FDA cultivated a reputation for competence and vigilance throughout the last century, and how this organizational image has enabled the agency to regulate an industr United States / Food and Drug Administration United States / Food and Drug Administration fast United States Food and Drug Administration USA Food and Drug Administration (DE-588)10985-X gnd rswk-swf Geschichte 1927-2010 gnd rswk-swf Drug Approval / United States Consumer Product Safety / United States Government Agencies / United States / History Government Regulation / United States Organizational Culture / United States Drugs Food and Drug Administration Pharmaceutical policy Research United States Health Political Science Social Science MEDICAL / Allied Health Services / General bisacsh MEDICAL / Pharmacology bisacsh Drugs / Research fast Pharmaceutical policy fast Geschichte Medizin Pharmaceutical policy United States Drugs Research United States Machtzuwachs (DE-588)7545408-7 gnd rswk-swf Organisationsstruktur (DE-588)4115464-2 gnd rswk-swf USA USA Food and Drug Administration (DE-588)10985-X b Organisationsstruktur (DE-588)4115464-2 s Machtzuwachs (DE-588)7545408-7 s Geschichte 1927-2010 z 1\p DE-604 Erscheint auch als Druckausgabe 0-691-14179-7 Erscheint auch als Druckausgabe 978-0-691-14179-4 http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=329845 Aggregator Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Carpenter, Daniel P. Reputation and power organizational image and pharmaceutical regulation at the FDA United States / Food and Drug Administration United States / Food and Drug Administration fast United States Food and Drug Administration USA Food and Drug Administration (DE-588)10985-X gnd Drug Approval / United States Consumer Product Safety / United States Government Agencies / United States / History Government Regulation / United States Organizational Culture / United States Drugs Food and Drug Administration Pharmaceutical policy Research United States Health Political Science Social Science MEDICAL / Allied Health Services / General bisacsh MEDICAL / Pharmacology bisacsh Drugs / Research fast Pharmaceutical policy fast Geschichte Medizin Pharmaceutical policy United States Drugs Research United States Machtzuwachs (DE-588)7545408-7 gnd Organisationsstruktur (DE-588)4115464-2 gnd |
| subject_GND | (DE-588)10985-X (DE-588)7545408-7 (DE-588)4115464-2 |
| title | Reputation and power organizational image and pharmaceutical regulation at the FDA |
| title_auth | Reputation and power organizational image and pharmaceutical regulation at the FDA |
| title_exact_search | Reputation and power organizational image and pharmaceutical regulation at the FDA |
| title_full | Reputation and power organizational image and pharmaceutical regulation at the FDA Daniel Carpenter |
| title_fullStr | Reputation and power organizational image and pharmaceutical regulation at the FDA Daniel Carpenter |
| title_full_unstemmed | Reputation and power organizational image and pharmaceutical regulation at the FDA Daniel Carpenter |
| title_short | Reputation and power |
| title_sort | reputation and power organizational image and pharmaceutical regulation at the fda |
| title_sub | organizational image and pharmaceutical regulation at the FDA |
| topic | United States / Food and Drug Administration United States / Food and Drug Administration fast United States Food and Drug Administration USA Food and Drug Administration (DE-588)10985-X gnd Drug Approval / United States Consumer Product Safety / United States Government Agencies / United States / History Government Regulation / United States Organizational Culture / United States Drugs Food and Drug Administration Pharmaceutical policy Research United States Health Political Science Social Science MEDICAL / Allied Health Services / General bisacsh MEDICAL / Pharmacology bisacsh Drugs / Research fast Pharmaceutical policy fast Geschichte Medizin Pharmaceutical policy United States Drugs Research United States Machtzuwachs (DE-588)7545408-7 gnd Organisationsstruktur (DE-588)4115464-2 gnd |
| topic_facet | United States / Food and Drug Administration United States Food and Drug Administration USA Food and Drug Administration Drug Approval / United States Consumer Product Safety / United States Government Agencies / United States / History Government Regulation / United States Organizational Culture / United States Drugs Food and Drug Administration Pharmaceutical policy Research United States Health Political Science Social Science MEDICAL / Allied Health Services / General MEDICAL / Pharmacology Drugs / Research Geschichte Medizin Pharmaceutical policy United States Drugs Research United States Machtzuwachs Organisationsstruktur USA |
| url | http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=329845 |
| work_keys_str_mv | AT carpenterdanielp reputationandpowerorganizationalimageandpharmaceuticalregulationatthefda |